Cell Cycle
-
SCH 900776 (MK-8776)
Catalog No. A11167 Chk1 抑制剂SCH 900776 (MK-8776)是靶向细胞周期检查点激酶1(Chk1)的药物,无细胞试验中IC50为3 nM,比作用于Chk2选择性高500倍。具有潜在的放射增敏和化学增敏活性。 了解更多 -
LY2603618 (IC-83)
Catalog No. A11036 Chk 抑制剂LY2603618 (IC-83)是一种chk2抑制剂,可与chk2结合并抑制其活性,这可能会阻止DNA损伤剂引起的DNA修复。 了解更多 -
BI6727 (Volasertib)
Catalog No. A10135 PLK 抑制剂BI6727 (Volasertib)是一种高效且选择性的polo样激酶(PLK)1抑制剂(在一组癌细胞系中,酶IC50 = 0.87 nM,EC50 = 11-37 nM)。 了解更多 -
HMN-214
Catalog No. A10452 -
TAK-960
Catalog No. A11146 -
ON-01910 (rigosertib)
Catalog No. A10673 PLK 抑制剂ON-01910 (rigosertib)通过涉及PI3K/AKT抑制和氧化应激诱导的双重作用机制对慢性淋巴细胞白血病细胞具有选择性的细胞毒性。 了解更多 -
MLN 0905
Catalog No. A12429 -
NMS-1286937
Catalog No. A13045 -
SBE 13 HCl
Catalog No. A14426 PLK 抑制剂SBE 13 HCl是PLK1的选择性抑制剂,对于PLK1,PLK3和PLK2,IC 50值分别为200pM,875nM和66μM。 了解更多 -
CCT241533 hydrochloride
Catalog No. A15038 Chk2 抑制剂CCT241533 hydrochloride是一种有效的丝氨酸/苏氨酸检查点激酶(Chk2)抑制剂,IC50为3 nM;显示在1 uM下与一组激酶的交叉反应最小。 了解更多 -
CCT244747
Catalog No. A15550 -
AAPK-25
Catalog No. A19085 Aurora/PLK dual 抑制剂AAPK-25 is a potent and selective Aurora/PLK dual inhibitor with anti-tumor activity, which can cause mitotic delay and arrest cells in a prometaphase, reflecting by the biomarker histone H3Ser10 phosphorylation and followed by a surge in apoptosis. 了解更多 -
Centrinone-B
Catalog No. A20855 PLK4 inhibitorCentrinone-B (LCR-323) is a potent and highly selective PLK4 inhibitor, with a Ki of 0.59 nM. 了解更多 -
Centrinone
Catalog No. A20858 PLK4 inhibitorCentrinone (LCR-263) is a selective and reversible inhibitor of polo-like kinase 4 (PLK4) with a Ki of 0.16 nM. 了解更多 -
GDC-0575 dihydrochloride
Catalog No. A21567 CHK1 inhibitorGDC-0575 dihydrochloride (ARRY-575 dihydrochloride) is an orally bioavailable CHK1 inhibitor, with an IC50 of 1.2 nM, and has antitumor activity. 了解更多 -
TAK-960 hydrochloride
Catalog No. A21703 PLK1 inhibitorTAK-960 hydrochloride is an orally available, selective inhibitor of polo-like kinase 1 (PLK1), with an IC50 of 0.8 nM at 10 μM ATP; TAK-960 hydrochloride also shows inhibitory activities against PLK2 and PLK3, with IC50s of 16.9 and 50.2 nM, respectively. 了解更多 -
AZD7762
Catalog No. A10113 -
CHIR-124
Catalog No. A11046 -
PF 477736
Catalog No. A11520 -
SCH900776 (S-isomer)
Catalog No. A12703 CHK1 抑制剂SCH900776 (S-isomer)是靶向细胞周期检查点激酶1(Chk1)抑制剂,无细胞试验中IC50为3 nM,比作用于Chk2选择性高500倍。具有潜在的放射增敏和化学增敏活性。 了解更多 -
BML-277
Catalog No. A13575 -
LY2606368
Catalog No. A13684 -
PD0166285
Catalog No. A15863 -
GDC-0575 (ARRY-575, RG7741)
Catalog No. A16811 -
Palbociclib
Catalog No. A14427 CDK 抑制剂Palbociclib是一种吡啶并嘧啶衍生的细胞周期蛋白依赖性激酶(CDK)抑制剂,具有潜在的抗肿瘤活性。 了解更多 -
LY2835219 (abemaciclib)
Catalog No. A12989 CDK4/6 抑制剂LY2835219 (abemaciclib)是一种细胞周期蛋白依赖性激酶(CDK)抑制剂,靶向CDK4(cyclin D1)和CDK6(cyclin D3)细胞周期途径,具有潜在的抗肿瘤活性。 了解更多 -
PD 0332991 HCl (Palbociclib)
Catalog No. A10701 CDK 4/6 抑制剂PD 0332991 HCl (Palbociclib)是一种高度选择性的CDK4/6抑制剂,它对CDK1/2/5,EGFR,FGFR,PDGFR,InsR等没有抑制活性,具有潜在的抗肿瘤活性。 了解更多 -
Flavopiridol (Alvocidib)
Catalog No. A10390 CDK 抑制剂Flavopiridol(Alvocidib)是一种细胞周期蛋白依赖性激酶抑制剂,与ATP竞争性抑制CDK,包括CDK1, CDK2, CDK4和CDK6,CDK9。作用于CDK1, 2, 4, 6,9比作用于CDK7更具有选择性,用于治疗慢性淋巴细胞性白血病。 了解更多 -
Dinaciclib (SCH 727965)
Catalog No. A11129 CDK 抑制剂Dinaciclib (SCH 727965)是一种有效且选择性的细胞周期蛋白依赖性激酶(CDK)抑制剂,选择性抑制CDK1,CDK2,CDK5和CDK9,IC50值分别为3、1、1和4 nM。 了解更多 -
BAY 1000394 (Roniciclib)
Catalog No. A12742 CDK 抑制剂BAY 1000394 (Roniciclib)是一种口服生物利用细胞周期蛋白依赖性激酶(CDK)抑制剂,具有潜在的抗肿瘤活性。 了解更多 -
PHA-793887
Catalog No. A10716 CDK 抑制剂PHA-793887是一种新型有效的CDK2,CDK5和CDK7抑制剂,IC50分别为8 nM,5 nM 和10 nM,作用于CDK2,5,和7比作用于CDK1,4,和9选择性高6倍以上。可在低浓度下靶向多种细胞周期蛋白依赖性激酶,并具有针对多种癌细胞的高活性。 了解更多 -
Roscovitine (Seliciclib)
Catalog No. A10806 CDK 抑制剂Roscovitine (Seliciclib)是一种CDK抑制剂,可优先抑制多种酶靶标,包括CDK2,CDK7和CDK9。 了解更多 -
PHA-767491
Catalog No. A11164 Cdc7/cdk9 抑制剂PHA-767491是一种有效的,具有ATP竞争性的双重cdc7/cdk9抑制剂 (IC50值分别为10和34 nM),可防止DNA复制的启动。 了解更多 -
Kenpaullone
Catalog No. A11220 CDK 抑制剂Kenpaullone是CDK1/细胞周期蛋白B(IC 50 = 400 nM),CDK2/细胞周期蛋白A(IC 50 = 680nM),CDK5(IC 50 = 850nM)的有效抑制剂,对其他激酶的作用要小得多。 了解更多 -
BMS-863233 (XL-413)
Catalog No. A13677 CDK 抑制剂BMS-863233,也称为XL-413,是一种具有潜在抗肿瘤活性的细胞分裂周期7同系物(CDC7)激酶抑制剂。 了解更多